Business Regulation & Regulated Industries

To the uninitiated, the combination of patent and US Food and Drug Administration (FDA) law applicable…

The move by the Food and Drug Administration (FDA) to regulate Laboratory Developed Tests (LDTs) as medical…

Introduction There has been a growing interest in the acquisition and sale of telehealth providers.…

There has been a notable uptick in clinical research sites being bought out by private equity and venture…

The recent growth in state healthcare transaction review laws is requiring parties to healthcare transactions…

This article is adapted from The Legal and Social Ramifications of Pandemics on Civil Rights and Civil…

On February 1, 2023, the Centers for Medicare and Medicaid Services (“CMS”) issued its final rule…

On February 1, 2023, the Centers for Medicare and Medicaid Services (“CMS”) issued its final rule…

A much-publicized 2003 KPMG survey concluded that nearly 70 percent of mergers and acquisitions (“M&A”)…

The purpose of this commentary is twofold: (1) to identify deficiencies in the 340B statute[1] related…

Acquisitions of public companies in pharma, biotech, and other life sciences industries are increasingly…

On February 1, 2023, the Centers for Medicare and Medicaid Services (“CMS”) will issue its final…

To the uninitiated, the combination of patent and US Food and Drug Administration (FDA) law applicable…

The move by the Food and Drug Administration (FDA) to regulate Laboratory Developed Tests (LDTs) as medical…

Introduction There has been a growing interest in the acquisition and sale of telehealth providers.…

There has been a notable uptick in clinical research sites being bought out by private equity and venture…

The recent growth in state healthcare transaction review laws is requiring parties to healthcare transactions…

This article is adapted from The Legal and Social Ramifications of Pandemics on Civil Rights and Civil…

On February 1, 2023, the Centers for Medicare and Medicaid Services (“CMS”) issued its final rule…

On February 1, 2023, the Centers for Medicare and Medicaid Services (“CMS”) issued its final rule…

A much-publicized 2003 KPMG survey concluded that nearly 70 percent of mergers and acquisitions (“M&A”)…

The purpose of this commentary is twofold: (1) to identify deficiencies in the 340B statute[1] related…

Acquisitions of public companies in pharma, biotech, and other life sciences industries are increasingly…

On February 1, 2023, the Centers for Medicare and Medicaid Services (“CMS”) will issue its final…